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In low-incidence countries in the European Union (EU), 
tuberculosis (TB) is concentrated in big cities, espe-
cially among certain urban high-risk groups including 
immigrants from TB high-incidence countries, home-
less people, and those with a history of drug and alco-
hol misuse. Elimination of TB in European big cities 
requires control measures focused on multiple layers 
of the urban population. The particular complexities of 
major EU metropolises, for example high population 
density and social structure, create specific opportu-
nities for transmission, but also enable targeted TB 
control interventions, not efficient in the general pop-
ulation, to be effective or cost effective. Lessons can 
be learnt from across the EU and this consensus state-
ment on TB control in big cities and urban risk groups 
was prepared by a working group representing various 
EU big cities, brought together on the initiative of the 
European Centre for Disease Prevention and Control. 
The consensus statement describes general and spe-
cific social, educational, operational, organisational, 
legal and monitoring TB control interventions in EU big 
cities, as well as providing recommendations for big 
city TB control, based upon a conceptual TB transmis-
sion and control model.
The city can have as much reduction of preventable 
disease as it wishes to pay for. Public health is pur-
chasable; within certain natural limitations a city can 
determine its own death rate.
Hermann Biggs, New York City Board of Health, Annual 
Report, 1915
Background
In low-incidence settings, which include most countries 
in the European Union (EU), tuberculosis (TB) is con-
centrated in big cities [1]. TB disproportionally affects 
certain, often overlapping, urban groups such as immi-
grants from TB high-incidence countries, homeless 
people, those with a history of drug and alcohol mis-
use, and people with a history of imprisonment [2–11]. 
Prevention and control of TB among these risk groups 
can be hampered by delayed diagnosis, onward trans-
mission and poor treatment adherence [12–16]. For 
effective TB control, services in EU big cities should 
be acceptable, accessible, adequate, appropriate and 
geared towards the needs of urban risk groups. In the 
last decade, innovative TB control activities in EU big 
cities have been reported, including mobile digital 
chest X-ray screening [16–19], the employment of com-
munity health workers and peer-educators [20,21], the 
use of mobile telephone-assisted or video-observed 
medication monitoring systems [22,23], and the appli-
cation of molecular epidemiology [24–27]. Systematic 
implementation of evidence-based and innovative 
approaches to improve early case finding, case hold-
ing and treatment completion in urban risk groups is 
urgently needed. Exchange of experience from dif-
ferent urban TB programmes in the EU will be key to 
achieving European TB control.
In February 2008, the European Centre for Disease 
Prevention and Control (ECDC) published the Framework 
Action Plan to fight tuberculosis in the European Union, 
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providing proposals on what needed to be done in EU 
Member States to decrease the burden of TB [28]. The 
report recognises the concentration of TB in hard-to-
find and hard-to-reach populations as one of the major 
challenges to TB control efforts across the EU and a key 
strategic element to reduce and eliminate TB. The EU 
action plan provides an opportunity to re-think urban 
TB control, specifically among vulnerable populations 
in the EU, and strengthen work through the exchange 
of experience, collaborative research, advocacy and 
cooperation. In this statement, we have summarised 
key evidence-based and expert opinion-led recommen-
dations to inform the control of TB in big EU cities. For 
each recommendation, we have provided a brief back-
ground and a summary of the evidence available.
Methods
Informal contacts have existed between some big cit-
ies in the EU for over a decade. In October 2005, the 
Municipality of Paris organised a conference on metro-
politan TB in Europe and the theme of TB in big cities 
was discussed at the 5th European TB conference of 
the International Union Against Tuberculosis and Lung 
Disease (The Union) in Dubrovnik in 2009 [29]. During 
the Wolfheze Conference in 2010 [30], TB control in big 
cities in Europe featured in the programme for the first 
time and as a result of this meeting ECDC agreed to 
facilitate a workshop on urban TB control in December 
2010. TB programme managers and TB control physi-
cians from 10 big cities in eight EU countries attended 
the event in Stockholm and a working group gradually 
developed and generated this consensus statement 
on TB control in big cities and urban risk groups in the 
EU. The preliminary outcomes of a survey on the epi-
demiology of TB in big cities in the EU, as well as the 
process and the progress of the working group, were 
presented at the 2011 Wolfheze conference.
This consensus statement is based upon a conceptual 
model of structural and intermediate determinants 
(explained in the next section) of TB exposure, infection, 
disease and treatment [31], as well as interventions for 
TB control, especially in urban risk populations (Figure 
1). Each section begins with a discussion of the back-
ground of general interventions and specific elements 
for TB control in big cities, and is then followed by 
agreed recommendations to achieve control of TB in EU 
cities. These recommendations are rated in accordance 
with the Scottish Intercollegiate Guidelines Network 
(SIGN) grading system (Table 1) [32]. Rating was per-
fomed by one of the authors (RWA) and subsequently 
ratified by the expert group Detailed information 
(checklists and critical appraisals) of the SIGN grading 
process is available on request from the corresponding 
author. The literature was selected by authors of the 
consensus statement in a non-systematic search. SIGN 
grading was developed for the assessment of evidence 
in clinical studies and is not necessarily directly appli-
cable to all public health interventions. Therefore a 
risk–benefit, feasibility, cost-effectiveness and value–
acceptability assessment of the recommendations has 
been added in addition to the SIGN grading (Table 2). 
Due to differences in the ratio of urban and national 
TB notification rates in EU Member States, this state-
ment has concentrated on urban TB and control in low-
incidence (<20 TB notifications/100,000 population) EU 
countries according to ECDC definition [33]. Although 
there is a great deal of relevant literature on urban 
TB and control outside the EU (especially in North 
America), for the purpose of this consensus statement 
the working group has focused on European publica-
tions when available.
Social determinants and interventions
General background
Social determinants, including structural (e.g. social, 
political, cultural and economic, health system) or 
intermediary (e.g. crowded living conditions) and the 
value of equity are major factors that influence health 
outcomes [34]. Wealth, health and infection inequali-
ties that influence TB morbidity and mortality rates 
exist in and between EU countries [35–38], and are 
probably affected by economic crises [39].
Social determinants and big cities
Social determinants of TB are not exclusive to big cit-
ies but urbanisation and the associated poverty and 
overcrowding that is more commonly found in these 
locations, impact on the levels of TB [40]. In many big 
cities outside and inside the EU, socio-economically 
disadvantaged populations are more prevalent. This 
is putting all residents at greater risk of TB acquisition 
but is particularly increasing the risk among certain 
urban subpopulations [2, 41–43]. Immigrants, legal or 
undocumented, form a substantial proportion of big 
city populations in the EU and can contribute consid-
erably to TB incidence [24,42]. Household overcrowd-
ing is often found in urban areas and is related to TB 
incidence [42,44]. Specific urban overcrowding has 
been described well in shelters for homeless people 
or facilities for people with drug misuse; two socially 
excluded groups that are often over-represented in 
EU big cities [7,18,19,24]. Social determinants are fun-
damental causes of TB in EU big cities and therefore 
solutions to control TB must tackle these issues [45]. A 
social outreach model of care has been advocated [46], 
including the role of a link worker who can enable inte-
grated health and social care, by, for example, resolv-
ing issues related to health, housing need, welfare 
benefits and immigration, as well as clinical manage-
ment issues [47]. 
Recommendations
Big city TB control programmes should:
1.1. advocate for sustained political commitment to 
emphasise the social determinants of health that 
put subgroups of the population at increased risk 
of TB;
1.2. investigate and monitor inequalities and socio-
economic deprivation and their links with TB in 
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Figure
Conceptual model of structural and intermediate determinants of tuberculosis and areas of possible interventions, based on 
the natural history of tuberculosis from exposure through to infection and disease and treatment
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   - Diagnostic delay of
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ExposurePre-exposure Latent infection Disease Treatment
TB: tuberculosis; HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection.
Table 1
Rating levels of the evidence used to make recommendations to inform tuberculosis control in big cities in the European 
Union, made in accordance with the Scottish Intercollegiate Guidelines Network (SIGN) grading system
Rating Study design Special conditions Level of evidence
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias If directly applicable to target population
A
1+ Well-conducted meta-analyses, systematic reviews, or 
RCTs with a low risk of bias
If directly applicable to target population 
and overall consistency of results
1++ or 1+ Extrapolated evidence
B
2++ 
High quality systematic reviews of case control or 
cohort or studies
If directly applicable to target population 
and overall consistency of results
High quality case control or cohort studies with a very 
low risk of confounding or bias and a high probability 




Well-conducted case control or cohort studies with 
a low risk of confounding or bias and a moderate 
probability that the relationship is causal
If directly applicable to target population 
and overall consistency of results
Extrapolated evidence
D3 Non-analytic studies, e.g. case reports, case series  
4 Expert opinion  
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias
  No supporting evidence
2- 
Case control or cohort studies with a high risk of 
confounding or bias and a significant risk that the 
relationship is not causal
RCT: Randomised controlled trial
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Table 2
Assessment of the recommendations to inform tuberculosis control in big cities in the European Union, by evidence 
grading, risk–benefit, feasibility, cost-effectiveness and value–acceptability
Recommendations Evidence grading Risk–benefit Feasibility Cost-effectiveness Value–acceptability
Recommendation 1.1 D Low/high Possible Unknown Unknown/unknown
Recommendation 1.2 D Low/high Feasible Unknown Unknown/unknowna
Recommendation 1.3 D Low/high Possible Unknown Unknown/unknowna
Recommendation 1.4 D Low/high Possible Unknown Unknown/unknowna
Recommendation 1.5 D Low/high Possible Unknown Unknown/unknowna
Recommendation 2.1.1 D Low/high Feasible Unknown Valued/acceptable
Recommendation 2.1.2 D Low/high Feasible Unknown Valued/acceptable
Recommendation 2.1.3 B Low/high Feasible Unknown Valued/acceptable
Recommendation 2.2 D Low/high Feasible Unknown Valued/acceptable
Recommendation 3.1 D Low/high Possible Unknown Justified/acceptableb
Recommendation 4.1 C Low/high Feasible Possible Valued/acceptable
Recommendation 4.2 D Low/high Feasible Yesc Unknown/acceptabled
Recommendation 4.3 C Low/high Feasible Yes Valued/acceptable
Recommendation 4.4 D Low/high Feasible Unknown Valued/acceptable
Recommendation 5.1 D Low/high Unknown Unknown Unknown
Recommendation 5.2 D Low/high Feasible Unknown Valued/acceptablee
Recommendation 5.3 D Low/high Unknown Unknown Unknown
Recommendation 5.4 D Low/high Unknown Unknown Unknown
Recommendation 5.5 D Low/high Unknown Unknown Unknown
Recommendation 6.1 D Mediumf/highg Unknown Yesh Valued/acceptablei
Recommendation 6.2 D Mediumf/highg Unknown Yesh Unknown
Recommendation 6.3 D Mediumf/highg Unknown Yesh Valued/acceptable
Recommendation 7.1 D Low/high Feasiblej Unknown Valued/acceptable
Recommendation 8.1 D Low/high Possible Unknown Unknown/unknown
Recommendation 8.2 D Low/high Possible Unknown Valued/acceptable
Recommendation 8.3 D Low/high Feasible Unknown Valued/acceptable
Recommendation 8.4 D Low/high Possible Unknown Valued/acceptable
Recommendation 8.5 D Medium6/high7 Possible Unknown Questioned/questioned
Recommendation 8.6 D Low/high Feasible Unknown Valued/acceptable
Recommendation 9.1 D Low/high Feasible Unknown Valued/acceptable
Recommendation 9.2 D Low/high Feasible Unknown Valued/acceptable
Recommendation 9.3 D Low/unknown Possible Unknown Valued/acceptable
a Acceptability of high cost interventions without clear immediate cost savings but with high cost savings in the future may be difficult in 
time of economic crisis and austerity.
b With education and information.
c For latent TB infection screening, not for radiographic screening for disease.
d Legal framework may be needed.
e Value and acceptability will vary between urban TB risk groups.
f Possible hepatotoxic and other adverse effects.
g High for the individual; unclear for public health. 
h For immigrants.
i Unclear for preventive treatment.
j Cost can be prohibitive.
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order to intervene with a comprehensive public 
health approach [28,37,38];
1.3. collaborate to promote suitable housing for home-
less people in order to prevent transmission of TB 
and promote cure in this population [48-51];
1.4. provide access to social support for all vulnerable 
populations, irrespective of their status [52-54];
1.5. identify barriers and promote access to healthcare 
services for all those at risk of TB [21].
Awareness: information and education 
interventions
General background
Targeted provision of information to raise awareness 
among high-risk groups, in the form of leaflets or 
through the Internet, has been used for diseases other 
than TB, such as diabetes, HIV or breast cancer [55,56]. 
There is an increased drive to use raising awareness as 
a measure for TB control and to improve knowledge of 
TB among high-risk groups and the staff who work with 
them [57].
Awareness and big cities
Initiatives for raising awareness, such as active infor-
mation and education strategies, should target urban 
TB risk groups, those working with urban TB risk 
groups, and healthcare professionals in urban areas 
[11,23]. To avoid stigmatisation, awareness of TB in 
risk groups in big cities can be improved on an oppor-
tunistic basis, for example, when a patient comes into 
contact with healthcare services for consultation or 
screening [11,58–61]. There is evidence from an educa-
tional intervention in London that promotion of screen-
ing in primary care can improve early identification of 
both active TB and latent TB infection (LTBI) [58].
Recommendations
Big city TB control programmes should:
2.1. implement a coordinated programme of education 
and training to raise and sustain awareness among 
affected risk groups and communities [11], front-
line professionals working with high-risk groups 
[11,21], and health and social care professionals, 
such as general practitioners [11,58,62];
2.2. involve affected communities in the design and 
delivery of training and awareness raising pro-
grammes, taking into account cultural, language 
and literacy issues [11].
Infection control in community settings
General background
Infection control (IC) is an essential component of 
TB control and prevention and is included in the EU 
Standards of TB Care [63]. Shortcomings in IC have 
been major contributors to nosocomial outbreaks, 
including outbreaks in European TB reference centres 
[64]. Poor ventilation and overcrowding have been driv-
ers of TB transmission in congregate settings such as 
homeless shelters, prisons and safe drug consumption 
facilities. General IC principles for healthcare settings 
can benefit these specific congregate venues [65]. New 
interest in IC has been awakened by the emergence of 
multidrug-resistant (MDR) and extensively drug-resist-
ant (XDR) TB [66].
Infection control in community settings and 
big cities
Nosocomial transmission of TB in urban hospitals 
[67,68], and effective IC measures in these health-
care settings [69], have been described in the EU. 
Transmission in hostels and shelters attended by risk 
groups, and prisons in big cities in the EU, have been 
suggested by conventional epidemiological studies [70] 
and strong evidence is supplied by molecular epide-
miological studies using DNA fingerprint cluster analy-
sis [13,16,19,71–75]. Congregate settings in big cities 
in the EU can implement hygienic measures (proper 
room ventilation and illumination, no overcrowding, 
cough hygiene) and organise TB awareness-raising 
activities. They can also implement administrative con-
trol activities (early guided referral of residents sus-
pected of having TB for diagnosis and isolation), and 
motivate residents to participate in contact tracing or 
radiographic screening [16,17,19]. IC can also prevent 
TB infection or disease among healthcare workers and 
social workers in big cities [13,65].
Recommendations
Big city TB control programmes should:
3.1. ensure implementation of IC measures in congre-
gate settings used by urban high-risk groups (in 
addition to healthcare settings); these should fol-




TB control depends on early case finding and success-
ful treatment [28]. Active case finding aims to identify 
those with TB who have not presented themselves to 
the healthcare system of their own accord, in order to 
reduce TB transmission [76]. Active case finding can be 
performed through symptom screening, questionnaire-
based screening (including risk factors), radiographic 
(e.g. chest X-ray) screening, sputum examination (e.g. 
microscopy, culture or rapid molecular techniques, 
including automated nucleic acid amplification tests). 
Reviews of contact tracing and immigrant screening in 
the EU [77,78], and effectiveness and cost-effective-
ness of TB screening, have been published recently 
[10]. Disparities in active case finding in the EU have 
been described [79].
Case finding and big cities
The assumption that urban TB risk groups will present 
promptly, complete a diagnostic process that is some-
times difficult and prolonged, and take treatment last-
ing a minimum of six months is not a basis for effective 
TB control [45]. Active case finding among urban 
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high-risk groups should be complemented by tailored 
strategies for completion of the diagnostic process 
and treatment. These strategies include low-threshold 
public health TB ‘one-stop shops’ with sufficient nurs-
ing, social and community healthcare worker staff, 
appropriate outpatient clinical follow-up or the ability 
to admit patients to general hospitals or modern-day 
sanatoria (also called tertiary TB treatment centres). 
Policies should be backed up by adequate legal frame-
works for social support and protection and ensure 
knowledge about and facilitate access to healthcare 
services [4,5,21,52,80]. Controversies and unresolved 
issues in active TB case finding among urban hard-
to-reach groups have been recently addressed [10]. 
Contact tracing may not be feasible or effective for 
all urban risk groups, but can be in specific popula-
tions such as household or professional contacts 
[5,13]. Indiscriminate radiographic screening of immi-
grants is described as inefficient and not cost-effec-
tive [10,76,79,81,82]. However, some interventions 
that may not be effective when applied to the general 
population may be highly effective or cost-effective 
when targeted at specific urban high-risk groups, for 
example, homeless people and prisoners [10,16,17,19, 
83–85]. Studies on longitudinal radiographic screening 
programmes for urban risk groups in the EU are limited 
but provide evidence that socially excluded and vulner-
able urban risk groups can be reached [18,86], and that 
TB transmission can be controlled [16,19]. The National 
Institue for National Health and Care Excellence (NICE) 
has recently published guidelines advising TB screen-
ing in hostels for homeless people and prisons [11,87]. 
ECDC and the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) have recently published 
guidance on prevention and control of infectious dis-
eases in people who inject drugs [88].
Recommendations
Big city TB control programmes should:
4.1. implement and monitor contact tracing according 
to national guidelines and international best prac-
tice consensus [21,78,89¬–91];
4.2. ensure that national guidelines for screening of 
immigrants are implemented [77];
4.3   consider targeted radiographic screening (e.g. 
mobile or static digital X-ray units) of urban high-
risk groups, especially homeless people, peo-
ple with drug and alcohol misuse, and prisoners 
[11,16–19,83,85];
4.4   implement measures such as TB ‘one-stop shops’ 
to ensure that suspected TB cases in urban high-
risk groups are not lost before confirmation or 
exclusion of disease [11,21,63].
Case holding and treatment
General background
After case detection, TB control is founded on support-
ing patients to start and complete a long and occasion-
ally complicated (e.g. due to adverse effects) course 
of treatment. The impact of poor compliance can be 
profound, both to the patient and to public health [31]. 
Treatment adherence is dependent on factors related 
both to the patient (e.g. language barriers or lifestyle 
factors) and to the provider (e.g. accessible, accept-
able, adequate, appropriate and flexible services 
including treatment supervision and enhanced case 
management). Treatment supervision, such as directly 
observed therapy (DOT), requires adequate staffing 
levels based upon TB notification rates [4,5,80,92]. 
Enhanced case management requires multidisciplinary 
services such as specialist TB nurses, outreach social 
workers, TB link workers (or peer-support workers) 
with attention for any legal, social, housing or finan-
cial problems [5,17,46,47]. Conventional incentives and 
enablers, such as prepaid travel cards for public trans-
port, can be used to increase adherence, as well as 
monetary incentives, which are controversial but have 
been demonstrated to be effective [93]. Innovative 
ways to increase adherence to TB treatment using mod-
ern technology should be explored as they have been 
in the field of human immunodeficiency virus (HIV) 
infections [22,23,94,95]. When patients are either too 
medically or socially complex to be treated in a general 
hospital or on an outpatient basis, modern-day sanato-
ria can be invaluable [96,97]. Cohort reviews are key to 
improving case management and have played a major 
role in increasing treatment completion rates [7,98,99].
Case holding and treatment and big cities
Failure to attend appointments with medical or public 
health services is well-known among certain urban risk 
groups for TB [4,15]. For immigrants, factors such as 
legal, cultural, and language issues, socio-economic 
barriers and lack of knowledge about the healthcare 
system can result in taking the wrong medication or 
poor treatment adherence [100]. People who are home-
less, or who have a history of drug or alcohol misuse, 
or of imprisonment, are all groups associated with poor 
adherence, and comprised 44% of cases lost to follow-
up in London [7,31,101]. However, treatment completion 
can be very high among drug and alcohol misusers and 
homeless people in an adequate urban TB control pro-
gramme with strict treatment supervision and poten-
tial mandatory isolation [16]. For case holding in big 
cities, the TB control programme should closely coop-
erate with related services, such as HIV programmes 
[63], services for people with a history of drug and 
alcohol misuse [88], prison services [102], asylum 
seeker services [53], and services for homeless people 
[13,16]. The use of supervised housing for homeless TB 
patients appears to be both effective and cost-effec-
tive [49, 50]. Outreach services can reduce hospitalisa-
tion and therefore costs [103, 104]. Establishment of TB 
link workers can reduce failed attendance through use 
of telephones, SMS reminders or accompanied refer-
rals [17,22,23,46,47]. Specific attention is needed for 
undocumented migrants to ensure completion of treat-
ment [52].
Recommendations
Big city TB control programmes should:
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5.1. be complemented with social support systems 
directed towards the different risk  groups, such 
as accommodation for homeless people or access 
to methadone replacement programs for people 
with drug misuse [11,49,50,88];
5.2. identify patients who can benefit from DOT prior to 
treatment, with DOT being  considered for patients 
with risk factors for non-adherence as part of a 
patient-centred care plan [11,63,105,106];
5.3. provide low-threshold and accessible services 
that are staffed according to TB notification rate 
and establish partnerships with other relevant 
healthcare providers working with groups at 
high risk of TB, to support treatment continuity 
[4,5,11,47,63,107,108];
5.4. consider provision of incentives and enablers, 
peer-support workers and modern information 
technology to improve treatment adherence and 
outcomes [11,17,22,23,46,47,93,94];
5.5. be supported by EU healthcare regulation allowing 
undocumented migrants to complete TB treatment 
in the country of diagnosis [52-54].
Latent tuberculosis infection 
General background
The primary aim of screening for LTBI is to prevent TB 
disease. Aspects of active screening for LTBI in the EU 
[76], a European consensus statement on TB contact 
tracing [78], ECDC guidance on the use of interferon-
gamma release assay (IGRA) for diagnosis of LTBI [109], 
and controversies and unresolved issues regarding 
LTBI screening of immigrants and urban risk groups, 
including cost-effectiveness [10], have been published 
elsewhere. Screening for LTBI should be risk-based 
and not population-based [110,111]. Priority for LTBI 
screening in EU countries is usually given to recent 
contacts, children, immunocompromised patients and 
healthcare workers [112].
Latent tuberculosis infection and big cities
Recent immigrants, who are usually overrepresented 
in big cities, and urban risk groups for TB are often 
screened for TB disease [16,17,77,113]. Testing for LTBI 
is less frequently reported [6,76]. Screening of immi-
grants for LTBI can be cost-effective depending on pre-
ventive treatment completion [10,81,114] but is often 
poorly implemented [115] and the expected reduction 
of TB incidence has been questioned [116]. Immigrant 
screening can be performed in primary care settings in 
big cities [58, 59] and this location has been reported 
to be acceptable to the immigrant population [117]. 
The management of LTBI in urban risk groups such as 
homeless people or people with drug misuse is contro-
versial. Although the prevalence of LTBI is likely to be 
higher than in the general population, screening oppor-
tunities are limited by the hard-to-reach and hard-to-
treat characteristics of these subgroups. Additionally, 
drug and alcohol misuse and co-infection with HIV or 
other blood-borne viruses increase the probability 
of adverse reactions to preventive treatment [10,13]. 
Identification of active TB among homeless people was 
found to be more important [118]. The prevalence of 
LTBI upon detention in European prisons can be high, 
but diagnosis of TB disease usually remains the prior-
ity [119,120]. Novel approaches to improve preventive 
treatment completion in deprived populations, such 
as shorter or simpler regimens, are urgently needed, 
and should be implemented as they have been in the 
United States [10,121,122]. 
Recommendations
Big city TB control programmes should
6.1. offer LTBI screening to urban risk groups only when 
an effective programme exists for active case find-
ing and holding in these groups;
6.2. offer LTBI screening according to national guide-
lines, accompanied by a clear plan on preventive 
treatment;
6.3. organise a risk-based approach to LTBI screening, 
prioritising people who are at highest risk of infec-
tion or progression [63,78,112,123].
DNA fingerprinting
General background
Recent advances in molecular biology have provided 
new tools to better comprehend the epidemiology and 
transmission of TB disease. Mycobacterium tuberculo-
sis strain genotyping or DNA fingerprinting has been 
widely used in population-based studies to determine 
the extent of ongoing TB transmission and risk factors 
in various communities [124,125]. Insights and appli-
cations of DNA fingerprinting in TB control have been 
described in review articles [126–128]. In the ECDC 
follow-up to the EU Action Plan to fight TB, genotyp-
ing of M. tuberculosis was proposed as a useful way of 
systematically monitoring disease transmission [129].
DNA fingerprinting and big cities
The contribution of DNA fingerprinting to conven-
tional epidemiological data in the context of urban TB 
control has been described elsewhere [125]. Briefly, 
molecular indications for epidemiological links and 
identification of risk factors for transmission are cru-
cial for understanding the specific epidemiology of 
TB in big cities, allowing the detection of risk groups 
and informing (targeted) public health interventions 
[13,16]. Urban TB cases are more often seen in foreign-
born patients than cases in rural areas because of the 
higher proportion of migrant population in these cities. 
Most of these cases have a reactivation of an infection 
acquired in the patient’s native country [26] However, 
DNA fingerprinting has revealed that in urban migrant 
cases, transmission is frequently also recent, more 
often than in non-urban migrant cases [24]. Molecular 
epidemiological studies identified factors for a higher 
risk of clustering, reflecting the risk of infection, such 
as alcohol or intravenous drug misuse, homelessness, 
or certain ethnic backgrounds [125]. They also con-
firmed high-risk sites for TB transmission in big cit-
ies, including congregate settings such as shelters for 
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homeless people or prisons. Fingerprinting can also 
support extension of outbreak investigations and has 
been used to monitor trends and evaluate interven-
tions, most specifically in urban areas [130].
Recommendations
Big city TB control programmes should:
7.1. complement routine surveillance activities and con-
tact tracing with molecular epidemiology to iden-
tify unexpected spreading of TB and outbreaks, 
and to evaluate interventions [125].
General policy, legal framework and 
organisation of services
General policy: general background
Organisation and policies of TB control in the EU have 
been discussed in review articles covering standards 
of care [63], contact tracing [78], immigrant screening 
[77], active case finding [76] and cost-effectiveness 
[112]. The organisation as well as the legal framework 
for TB control differs between EU countries. These dif-
ferences reflect variations in service delivery models, 
infectious disease law, public health responsibilities, 
organisation and legal background of screening and 
the implementation of mandatory isolation [79].
General policy and big cities
Organisational aspects of big city TB control have 
recently been described [5]. Lack of central planning, 
political commitment and mechanisms to commission 
city-wide services have created barriers to implemen-
tation of evidenced-based and cost-effective services 
for case finding and case holding [17]. Increasing 
rates of TB have been found where big city TB control 
systems are fragmented and involve a high number 
of clinical settings [4,131]. Many of the high-risk TB 
patients found in big cities have complex social, medi-
cal and economic needs, and multi-disciplinary teams, 
networking, for example, with experts in relevant co-
morbidities such as HIV and hepatitis C and community 
and patient groups and sharing of experience between 
practitioners, are important in the organisation and 
provision of care in these settings. 
 Legal framework general background
Multiple laws can provide the legal framework for 
TB control in a country. Infectious disease acts and 
reports regulate the various responsibilities of national 
and local authorities, notification or reporting and sur-
veillance of TB or TB-HIV, screening and mandatory 
isolation in case of threats to public health [132–134]. 
International legislation (e.g. Universal Declaration of 
Human Rights European Convention on Human Rights 
[135,136]) state that any application of restrictions, 
including mandatory isolation, requires (i) a legal basis 
and (ii) reasonable evidence that the restrictions are 
necessary to protect public health. The public health 
argument for compulsory TB screening of immigrants 
and mandatory isolation is sometimes questioned 
[137,138].
Legal framework and big cities
A legal framework for notification should provide the 
information for surveillance, cross-sectional stud-
ies and cohort reviews in big cities. [7,98,99] Non-
compliant infectious TB patients are common in EU big 
cites, especially among urban TB risk groups [31]. The 
use of mandatory isolation is rarely used in some big 
cities in the EU [139]. Legal frameworks for mandatory 
isolation can be part of a successful urban TB control 
programme, if implemented when extensive attempts 
to support the patient have failed, for example through 
DOT, incentives and enablers, and social support [16].
Recommendations: 
Big city TB control programmes should:
8.1. be supported by high-level political commitment;
8.2. be organised to ensure accessibility for patients 
and include sufficient staff and expertise 
[4,5,11,80];
8.3. promote strong collaboration and coordination 
between sectors as a prerequisite to ensure deliv-
ery of the proposed recommendations;
8.4. have community and patient engagement pro-
grammes and address the problem of stigmatisa-
tion [58–61];
8.5. use involuntary isolation only as a measure of last 
resort under humane conditions;
8.6. contribute to a European network to facilitate the 
exchange of experience between programmes and 
allowing external assessment.
Strategy, monitoring and evaluation 
General background
To reach and sustain the goal of eliminating TB in 
Europe it is fundamental that countries develop stra-
tegic TB control plans tailored to their own epidemio-
logical situation. The ECDC Framework Action Plan to 
fight tuberculosis in the European Union and its follow-
up provides areas for strategy development, including 
monitoring and evaluation, which can serve as a basis 
for a country’s plan [28, 129]. Outcome assessment 
should be supported by robust and quality-assured sur-
veillance and laboratory systems, and linked to molec-
ular epidemiology where possible [28,129]. Systematic 
cohort reviews are of great value to improve the quality 
of data for every TB case and are key to the evaluation 
of TB control programmes by identifying problematic 
issues and gaps in case management [7,98].
Strategy, monitoring and evaluation of TB 
programmes and big cities
In countries where there is an identified problem with 
TB accumulating in vulnerable groups in big cities, 
the TB control strategy should be adapted to target 
those specific challenges and needs. Evaluation of big 
city TB programmes, internal and external, should be 
performed regularly in order to identify gaps in ser-
vices and be based upon ECDC-proposed indicators 
to monitor progress towards elimination [129], such 
as notification rates (including sputum smear positive 
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TB), paediatric TB, diagnostic delay, treatment adher-
ence rates, treatment outcome, cost-effectiveness and 
social support [5,17,99]. High-risk deprived communi-
ties as well as civil society can be engaged in such a 
process. DNA fingerprinting can monitor trends and 
evaluate interventions, most specifically in urban 
areas [16,19,125].
Recommendations
Big city TB control programmes should:
9.1. implement a continuous process of programme 
evaluation that will inform strategy development 
and include independent external peer review;
9.2. perform review of case detection and cohort 
review of case management and treatment out-
come. Reviews should include analysis by urban 
risk group [98, 140];
9.3. collaborate to evaluate targeted interventions 
in big cities, such as molecular epidemiology, to 
establish additional benefits in TB control [125].
Conclusion
In low-incidence EU countries TB is increasingly con-
centrated in big cities. There is an urgent need for the 
systematic implementation of effective, cost-effective, 
evidence-based and innovative approaches and tools 
to improve early case finding, case holding and treat-
ment completion in metropolitan areas, especially 
among vulnerable groups [28]. The working group for 
TB control in big cities and urban risk groups in the 
EU has formulated 32 recommendations for big city TB 
control in nine areas of possible interventions. These 
recommendations resulted from a consensus process, 
and were prepared as precisely as possible but owing 
to the consensus approach, some were formulated as 
considerations. This was necessary because the epi-
demiological background of TB may differ between big 
EU cities, some interventions may not be available in 
all countries and cities, and there are limitations to 
what the working group can instruct EU Member States 
to do. Some of the recommendations are not strictly 
specific to big cities, because there is some overlap 
between urban TB control and general principles, and 
therefore the working group agreed not to mention cer-
tain issues, such as nosocomial IC, in the recommenda-
tions, when it was considered to be a general principle. 
Overall, this consensus statement demonstrates that 
at present the level of evidence for these recommenda-
tions to achieve control of TB in EU cities and among 
urban risk groups is limited and should be improved. 
Exchange of experience, collaborative research, advo-
cacy and cooperation between different urban TB pro-
grammes in the EU will be instrumental to achieving TB 
control.
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